This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzalgo, M. L. Articles by Schoenberg, M. P. Search for Related Content PubMed PubMed Citation Articles by Gonzalgo, M. L. Articles by Schoenberg, M. P.

Prognostic Significance of Preoperative Molecular Serum Analysis in Renal Cancer

The James Buchanan Brady Urological Institute [M. L. G., C. F. E., B. J. T., S. H., D. S., M. P. S.] and Oncology Center [S. M. L.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, and Department of Urology, Emory University School of Medicine, Atlanta, Georgia 30322 [F. F. M.]

Purpose: We evaluated the postoperative clinical course of patients with renal cancer identified preoperatively by microsatellite analysis to examine the correlation between microsatellite alterations and risk of disease recurrence and patient mortality 2 years after nephrectomy.

Experimental Design: A panel of 28 microsatellite markers was used previously to assess loss of heterozygosity and microsatellite instability in urine, serum, and tumor DNA of 30 patients with clinically organ-confined renal masses who underwent partial or radical nephrectomy. The clinical reports and imaging data in the medical records of patients with a minimum follow-up of 2 years were retrospectively reviewed to determine their postoperative course.

Results: Two-year follow-up was available for the 30 patients (100%) who entered the study. Mean age was 61.6 ± 12.9 years (range, 21–77 years). Tumor stage was associated with patient mortality (P = 0.03). Tumor grade was associated with mortality (P = 0.03) and disease recurrence (P < 0.01). The frequency of microsatellite alterations (loss of heterozygosity) found in the preoperative serum of patients with renal masses served as a prognostic indicator for disease recurrence (P < 0.01).

Conclusions: Analysis of microsatellite alterations found in preoperative blood samples is a promising method for the detection of renal cancer. The presence of frequent molecular changes in preoperative serum was associated with disease recurrence. These findings suggest a role for microsatellite analysis in future studies attempting to stratify patients with clinically organ-confined renal cancer into low- and high-risk prognostic groups. Larger prospective randomized trials are needed to validate the clinical utility of this observation.

This article has been cited by other articles:

				P. Schurr, S. Wolter, J. Kaifi, U. Reichelt, H. Kleinhans, R. Wachowiak, E. Yekebas, T. Strate, V. Kalinin, R. Simon, et al. Microsatellite DNA Alterations of Gastrointestinal Stromal Tumors Are Predictive for Outcome Clin. Cancer Res., September 1, 2006; 12(17): 5151 - 5157. [Abstract] [Full Text] [PDF]

				M. O. Hoque, S. Begum, O. Topaloglu, C. Jeronimo, E. Mambo, W. H. Westra, J. A. Califano, and D. Sidransky Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer Cancer Res., August 1, 2004; 64(15): 5511 - 5517. [Abstract] [Full Text] [PDF]

				C. F. Eisenberger, W. T. Knoefel, M. Peiper, P. Merkert, E. F. Yekebas, P. Scheunemann, K. Steffani, N. H. Stoecklein, S. B. Hosch, and J. R. Izbicki Squamous Cell Carcinoma of the Esophagus Can Be Detected by Microsatellite Analysis in Tumor and Serum Clin. Cancer Res., September 15, 2003; 9(11): 4178 - 4183. [Abstract] [Full Text] [PDF]